via WHO
The drug developed by Texas A&M and University of Texas MD Anderson Cancer Center scientists could be an effective treatment for COVID-19 and other illnesses.
There’s a new drug in development that could prevent the next global pandemic. Researchers at the Texas A&M University Health Science Center (Texas A&M Health) and University of Texas MD Anderson Cancer Center are testing PUL-042, an inhaled therapeutic that provides broad protection against a range of life-threatening respiratory infections.
Results from a recent phase 2 clinical trial conducted through Houston-based biotechnology company Pulmotect, Inc. showed that it may be an effective treatment for COVID-19 and other respiratory illnesses. Patients in the trial treated with inhaled PUL-042 showed improvement in cough and shortness of breath more quickly than those who received a placebo treatment. They also experienced fewer hospitalizations and intensive care admissions.
Inhaled PUL-042 stimulates the lungs’ innate immune system, protecting against a wide variety of respiratory pathogens. The scientists behind it think PUL-042 could be directed against all existing and future variants of the COVID-19 virus, as well as future pandemics. Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
“We have not found a virus PUL-042 cannot work against in the lungs, in animal studies,” said Dr. Colin Broom, CEO of Pulmotect. “As an easily administered inhaled therapy, PUL-042 could have value in reducing the impact of COVID-19 irrespective of the development of further variants. It also has potential utility for other patient populations which we plan to explore, including immunosuppressed cancer patient.”
The innate immune system is the body’s first line of defense against invading pathogens. When germs and foreign substances enter the body, the innate immune system responds quickly to fight them off. PUL-042, the first drug in its class, is composed of two small synthetic molecules and works by stimulating specific innate immune receptors in the lung lining within minutes. Protection only lasts for about three to five days, but it can be repeatedly administered once every few days.
PUL-042 was discovered by Magnus H??k, regents and distinguished professor at the Texas A&M Health Institute of Biosciences and Technology, and Dr. Burton Dickey, chair of the pulmonary department at MD Anderson Cancer Center.
“The lungs are the point of entry for many viruses and bacteria. By activating the innate immune defense of the lungs, PUL-042 can provide effective protection against a wide range of deadly pathogens,” H??k said. “We believe that if we had this therapy available in December of 2019, we could have prevented the COVID-19 pandemic and avoided the 6 million lives lost.”
The Food and Drug Administration approved Pulmotect to begin two human clinical trials of PUL-042 last year, one focused on protection and another on treatment for COVID-19. Funding support for the trials was provided by the U.S. Department of Defense.
Original Article: New Inhaled Therapeutic Shows Promising Results Against Most Known Respiratory Infections
More from: Texas A&M University | University of Texas MD Anderson Cancer Center
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
PUL-042
- Osteoporosis and resistance training
THE phrase “out of sight and out of mind” applies perfectly to our bones.“We rarely pay attention to our bones,”says family physician Dr Sasha Farrier who sees patients at the ...
- 4 Bedroom Home in Bloomington - $675,000
These owners upgraded the main-floor laundry adding multiple cabinets, work surface, hanging rack and pull-outs. The second level landing provides outstanding views of the main activity and directs ...
- 55 Creative Teacher Appreciation Week Ideas to Say 'Thank You'
Once finished, they can fold them up and place them in a glass jar so their teacher can pull one out and read it when they’re having a bad day. Think about what class a teacher teaches and then find a ...
- Kent pitches West Middlesex past Mercer
Affectionately known as “Clark” by his West Middlesex teammates, Logan Kent did his best Superman impression Friday afternoon.
- Jim Pillen, Nebraska's members of Congress on the aftermath of the tornadoes in Nebraska
Bacon said he expects a massive outpouring from Nebraskans because Nebraskans always pull together and take care of each other. He said talks have already begun with federal emergency officials ...
Go deeper with Google Headlines on:
PUL-042
[google_news title=”” keyword=”PUL-042″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inhaled therapeutic
- Therapeutic Role of Nitric Oxide in Respiratory Disease
The anatomic target of inhaled nitric oxide (NO) is the vascular smooth muscle cells that surround the small resistance arteries in the lungs. As NO diffuses through the alveolar membrane ...
- Comparison of Inhaled Corticosteroids: An Update
Conclusions: Current evidence suggests that all of the inhaled corticosteroids have sufficient therapeutic indexes to provide similar efficacy and safety in low to medium doses. Whether or not ...
- FTC Targets ‘Junk’ Patents Including Novo’s Ozempic, GSK’s Trelegy Ellipta and Other Drugs
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their ...
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant ...
- MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for ...
Go deeper with Google Headlines on:
Inhaled therapeutic
[google_news title=”” keyword=”inhaled therapeutic” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]